Summary & Overview
HCPCS M1324: Intravitreal or Periocular Corticosteroid Injection
HCPCS Level II code M1324 designates care for patients who received an intravitreal or periocular corticosteroid injection, including agents such as triamcinolone, dexamethasone (including intravitreal implants), and fluocinolone intravitreal implants. This code captures a range of ophthalmic corticosteroid administration procedures used in managing retinal and periocular inflammatory or edematous conditions. Nationally, accurate reporting of M1324 matters for monitoring utilization of sustained-release steroid implants, tracking outpatient ophthalmic procedural volumes, and aligning coverage and payment policies across major payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and the procedural scope represented by M1324. The publication outlines common billing modifiers and payer considerations where available, presents benchmark and coverage themes, and highlights policy or coding nuances relevant to outpatient ophthalmic corticosteroid administration. Intended audiences include practice managers, billing professionals, and policy analysts seeking a national-level summary of coding, site-of-service implications, and payer coverage context for intravitreal and periocular corticosteroid injections.
Billing Code Overview
HCPCS Level II code M1324 applies to patients who received an intravitreal or periocular corticosteroid injection. Examples include triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, and fluocinolone intravitreal implant.
-
Service type: Ophthalmic corticosteroid injection procedures
-
Typical site of service: Eye clinic, ambulatory surgery center, or outpatient hospital setting
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of diabetic macular edema presents to the ophthalmology clinic with decreased central vision and retinal thickening on optical coherence tomography (OCT). After assessment by the retina specialist, a decision is made to perform an intravitreal corticosteroid injection (e.g., preservative-free triamcinolone or a dexamethasone intravitreal implant) to reduce macular edema and improve visual acuity. The procedure occurs in an ambulatory surgical center or office procedure room: the patient is consented, topical antisepsis and anesthesia are applied, a sterile eyelid speculum is placed, and the drug is injected through the pars plana under aseptic technique. Post-injection care includes intraocular pressure check, short observation for acute complications, discharge instructions, and scheduling of follow-up OCT and clinic visit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity substantially exceeds typical for an intravitreal injection and documentation supports unusual effort. |
23 | Unusual anesthesia | Use when general anesthesia or monitored anesthesia care (MAC) is medically necessary for the injection, per documentation. |